IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

IN RE:	)	
'318 PATENT INFRINGEMENT LITIGATION	)	**Civ. No. 05-356-(SLR) (consolidated)**

DEFENDANTS' DISCLOSURES PURSUANT TO 35 U.S.C. § 282

Defendants Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc. ("Barr") and Alphapharm Pty Ltd. (collectively "Defendants"), believe that their pleadings, written discovery responses, in conjunction with the expert reports submitted by the parties, and the deposition testimony provided in this matter are more than sufficient to meet Defendants' duties pursuant to 35 U.S.C. § 282. For example, the information requested by Section 282 is contained in at least the following pleadings or discovery exchanged in this case (all of which are incorporated herein by reference):

(1) Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc.'s Rule 26(a)(1) Initial Disclosures;

(2) Barr's Responses (and supplementation of responses) to Plaintiffs' discovery, including document requests, interrogatories, and request to admit regarding invalidity, including but not limited to Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc.'s Objections and Responses to Plaintiffs' Interrogatories Nos. 2 and 4;

(3) Co-Defendants Alphapharm Pty Ltd., Mylan Pharmaceuticals, Inc. and Mylan Laboratories, Inc., Purepac Pharmaceutical Co. and Alpharma Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc., Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd., Teva Pharmaceutical U.S.A. and Teva Pharmaceutical Industries Ltd.'s Responses (and

supplementation of responses) to Plaintiffs' discovery, including document requests, interrogatories, and request to admit regarding invalidity, such as Teva Pharmaceutical U.S.A. and Teva Pharmaceutical Industries Ltd.'s Second Supplemental Response to Interrogatory No. 2 of Plaintiffs' First Set of Interrogatories;

(4) Opening, Responsive, and Rebuttal Expert Reports of Drs. Levey and Domino;

(5) Depositions of Drs. Levey and Domino;

(6) Barr's Opening and Answering Claim Construction Briefs and Barr's brief in Opposition to Plaintiffs' Motion for Partial Summary Judgment Regarding Anticipation; and

(7) Defendants' Statement of Issues of Law, Issues of Fact, Trial Witness List and Trial Exhibit List contained in Exhibits 3, 5, 7, 9, and 11 of the Proposed Pretrial Order.

Nonetheless, out of an abundance of caution, Defendants provide the following list of patents and publications in which the information required by 35 U.S.C. § 282 is set forth:

No.	Title	Date	Page Nos.
1	British Patent No. 942,200 Titled: *A Method of Obtaining Galanthamine Hydrobromide*	1962	1-2
2	Albuquerque, E. *Allosterically Potentiating of Nicotinic Receptors as a Treatment Strategy for Alzheimer's Disease*, Behavior Brain Research, Vol. 113	(2000)	199-206
3	Ancoli-Israel S., *et al.*, *Effects of Galatamine Versus Donepezil on Sleep in Patients with Mild to Moderate Alzheimer Disease and Their Caregivers: A Double-Blind, Head-to-Head, Randomized Pilot Study*, Alzheimer Disease And Associated Disorders, Vol. 19	(2005)	240-245
4	Antuono, P.S., *et al.*, *Effectiveness and Safety of Velnacrine for the Treatment of Alzheimer's Disease: A Double-Blind, Placebo-Controlled Study. The Mentane Study Group*, Archives of Intern. Med., Vol. 155	(1995)	1766-1772
5	Baraka A, S. Harik, *Reversal of Central Anticholinergic Syndrome by Galanthamine* J.A.M.A., 238	(1977)	2293-2294
6	Bartus, R, *et al.*, *The Cholinergic Hypothesis of Geriatric Memory Dysfunction*, Science, Vol. 217	(1982)	408-418
7	Bartus, R, *et al. The Cholinergic Hypothesis: A Historical Overview, Current Perspective, and Future Directions*, Memory Dysfunctions: An Integration of Animal and Human Research from Preclinical Perspectives, Annals of the New York Academy of Sciences, 444	(1985)	332-358
8	E. Giacobini, "Cholinesterase Inhibitors Do More Than Inhibit Cholinesterase," in Becker & Giacobini, eds., Alzheimer Disease: From Molecular Biology to Therapy	(1996)	188-204
9	Becker, R.E., *et al.*, *Effects of Metrifonate on Cognitive Decline in Alzheimer Disease: A Double-Blind, Placebo-Controlled, 6-month*	(1998)	54-57

No.	Title	Date	Page Nos.
	study, Alzheimer Dis. Assoc. Disord. 12(1)		
10	Bhasker PA, *Medical Management of Dementia*, The Antiseptic, 71(1)	(1974)	45-47
11	Blass, J.P., *et al.*, *Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Two Doses of Metrifonate in Patients with Mild-to-Moderate Alzheimer's Disease: the MALT study*, Alzheimer's Dis. Assoc. Dis. J.,14(1)	(2000)	39-45
12	Beermann, B., *Side Effects of Long Acting Cholinesterase Inhibitors*, Acta. Neurol. Scand. Suppl., 149	(1993)	53-54
13	Bonner, T, *et al. Identification of a Family of Muscarinic Acetylcholine Receptor Genes*, Science, Vol. 237 Issue 4814	(1987)	527-532
14	Braga, *et al.*, *Effects of Tacrine, Velnacrine (HP029),Suronacrine (HP128), and 3,4-Diaminopyridine on Skeletal Neuromuscular Transmission in Vitro*, Brit. J Pharmacology, 102(4)	(1991)	909-915
15	Braida, Sala, *Eptastigmine: 10 Years of Pharmacology, Toxicology, Pharmacokinetics, and Clinical Studies*, CNS Drug Reviews, 7(4)	(2001)	369-386
16	Bretagne M, *et al., Essais cliniques en anesthesiology d'un nouvel anticholinesterasique la Galanthamine*, Anesthesie Analgesie Reanimation, Vol. 1	(1965)	286-292
17	Brinkman, S.D., *et al., A Dose-Ranging Study of Lecithin in the Treatment of Primary Degenerative Dementia (Alzheimer Disease)*, J Clinical Psychopharmacol., Vol. 2	(1982)	281-285
18	Brinkman, S.D., *et al., Lecithin and Memory Training in Suspected Alzheimer's Disease*, Journal of Gerontology, Vol. 37	(1982)	4-8

No.	Title	Date	Page Nos.
19	Bukatina, *et al.*, *Effectiveness of Amiridin in Senile Dementia of the A Type*, Translated from Zhurnal Nevropatologii i Psikhiatrii, 91(9)	(1991)	53-58
20	Christie, J.G., *et al. Effects of Choline and Lecithin on CSF Choline Levels and on Cognitive Functioning in Patients with Presenile Dementia of the Alzheimer Type*, Choline and Lecithin in Brain Disorders, Vol. 5	(1978)	377-389
21	Coyle, *Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation*, Science, Vol. 219	(1983)	1184-1190
22	Coyle, *Nicotinic Acetylcholine Binding Sites in Alzheimer's Disease*, Brain Research, Vol. 371	(1985)	146-151
23	Cozanitis DA, *Galanthamine Hydrobromide, a Longer Acting Anticholinesterase Drug, in the Treatment of Central Effects of Scolpamine (Hyoscine)*, Anaesthesist, 26	(1977)	649-50
24	Cozanitis DA, *L'hydrobromide de Galanthamine: Unsubstitut du Sulfate D'eserine (Physostigmine) pour le Traitement des Effects Cerebraux dex Substances Anti-Cholinergiques*, Nouv. Presse Med., 7(45)	(1978)	4152
25	Cozanitis DA, *Galanthamine Hydrobromide Versus Neostigmine A Plasma Cortisol Study in Man*, Anaesthesia, 29(2)	(1974)	163-168
26	Cozanitis DA, *et al. The Effect of Galanthamine Hydrobromide on Plasma ACTH in Patients Undergoing Anaesthesia and Surgery*, ACTA Anaesthesiol Scand., 24(3)	(1980)	166-168
27	Cozanitis DA, *et al.*, *A Comparative Study of Galanthamine Hydrobromide and Atropine/Neostigmine in Conscious Volunteers*, The Anaesthesist	(1971)	416-421
28	Cowen, P.J. *Toxic psychosis with antihistamines reversed by*	(1979)	556-557

No.	Title	Date	Page Nos.
	physostigmine, Postgraduate Medical Journal, Vol. 55		
29	Coyle, J., Kershaw, P., *Galantamine, a Cholinesterase Inhibitor that Allosterically Modulates Nicotinic Receptors: Effects on the Course of Alzheimer's Disease*, Biol. Psychiatry, Vol. 46	(2001)	289-299
30	Cummings, J.L., *et al.*, *The Efficacy of Metrifonate in Improving the Behavioral Disturbances of Alzheimer's Disease Patients*, Journal of Geriatr. Psychiatry Neurol., 50	(1998)	101-108
31	Cummings, J.L. *Metrifonate: Overview of Safety and Efficacy*, Pharmacotherapy, 18: (2, Pt 2)	(1998)	S43-S46
32	Daskalov D, *et al. Nivalin Application and Rehabilitation Treatment of Cerebral Diseases with Aphasic Syndromes*, MBI Medico-Biologic Information, 3	(1980)	9-11
33	Davis, B. *et al. Cholinergic Mechanisms and Anterior Pituitary Hormone Secretion*, Society of Biological Psychiatry, Vol. 15 No. 2	(1980)	303-318
34	Davis KL, *et al.*, *Physostigmine: Improvement of Long-Term Memory Processes in Normal Humans*, Science, 201(4352)	(1978)	272-74
35	Davis KL, *et al.*, *Enhancement of Memory Processes in Alzheimer's Disease with Multiple-Dose Intravenous Physostigmine*, The Am. J. of Psychiatry, 139(11)	(1982)	1421-1424
36	Davis KL, *et al.*, *Oral Physostigmine in Alzheimer's Disease*, Psychopharmacology Bulletin, 19(3)	(1983)	451-453
37	Davis KL, *et al.*, *Cholinergic Drugs in Alzheimer's Disease*, New England Journal of Medicine, 315(20)	(1986)	1286-1287
38	Davis, KL, *et al. Oral Tetrahydroaminoacridine in Long-term*	(1986)	1241-1245

No.	Title	Date	Page Nos.
	Treatment of Senile Dementia, Alzheimer's Type, New England Journal of Medicine, 315(20)		
39	DiSclafani, A. *et al. Drug-induced psychosis: Emergency diagnosis and management*, Psychosomatics, Vol. 22 No. 10	(1981)	845-855
40	Domino E, *Galanthamine: Another Look at an Old Cholinesterase Inhibitor*, Current Research in Alzheimer's Therapy Cholinesterase Inhibitors, eds. E. Giacobini and R. Becker	(1988)	295-303
41	Domino, E.F., *et al. Effects of Oral Lecithin on Blood Choline Levels and Memory Tests in Geriatric Volunteers*, Aging, Vol. 19	(1982)	393-397
42	Domino, *et al.*, *Effects of Oral Phosphatidylcholine on Mouse Brain Choline and Acetylcholine*, Arch. Int .Pharmacodyn, Vol. 265	(1983)	49-54
43	Drachman D., *et al.*, *Human Memory and the Cholinergic System A Relationship to Aging*, Archives of Neurology, Vol. 30	(1974)	113-121
44	Drachman, D. *Treatment of Alzheimer's disease: new outlooks for the future*, Normal Aging, Alzheimer's Disease and Senile Dementia Aspects on Etiology, Pathogenesis, Diagnosis and Treatment	(1985)	307-308
45	Drachman, D. *et al. Memory Decline in the Aged: Treatment with Lecithin and Physostigmine*, Neurology, Vol. 32	(1982)	944-949
46	Dubois, B., *et al.*, *A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Metrifonate in Patients with Probable Alzheimer Disease*, Int. J. Psychiat., Vol. 14	(1999)	973-982
47	Ettiene, *et al. Lecithin in Alzheimer's Disease*, Lancet, Vol. 2	(1976)	1206
48	Edelstein, P. *et al. Physostigmine and Lithium Response in the*	(1981)	1078-1081

No.	Title	Date	Page Nos.
	Schizophrenias, American Journal of Psychiatry, 138:8		
49	Giacobini, E., *Long-Term Stabilizing Effect of Cholinesterase Inhibitors in the Therapy of Alzheimer's Disease*, J. Neural Tran Supp., 62	(2002)	181-187
50	Göpel W, *et al.*, *Erfahrungen mit Nivalin in der Neurologischen Therapie*, Psychiat. Neurol. Med. Psychol., 23	(1971)	712-718
51	Greenwald B, *et al. Neurotransmitter Deficits in Alzheimer's Disease: Criteria for Significance,* Journal of the American Geriatrics Society, May 31(5)	(1983)	310-316
52	Geerts, H., *et. al., Brain Levels and Acetylcholinesterase Inhibition With Galantamine and Donepezil in Rats, Mice, and Rabbits,* Brain Research, 1033	(2005)	186-193
53	Haroutunian V, *et al. Cholinergic Modulation of Memory in Rats,* Psychopharmacology, (Berlin) 87(3)	(1983)	266-271
54	Haroutunian V, *et al. Pharmacological Alleviation of Cholinergic Lesion Induced Memory Deficits in Rats*, Life Sciences, 37(10)	(1985)	945-952
55	Hasan, M.K. *et al. Reversible Toxic Psychosis*, AFP, Vol. 22 No. 10	(1979)	89-92
56	Hornsperger, *et al., Trimethylsilylated Triflouromethyl Ketones, A Novel Class of Acetylcholinesterase Inhibitors: Biochemical and Pharmacological Profile of MDL 73.745,* Biochem. Soc Trans, 22(3)	(1994)	758-763
57	Hsieh J, *et al., High-Performance Liquid Chromatographic Determination of Tetrahydroaminoacridine in Human and Rat Tissues Using a Rapid Sep-Pak C18 Extraction,* Journal of Chromatography, 274	(1983)	388-392

No.	Title	Date	Page Nos.
58	Hoerr, *et al.*, *Ensaculin (KA-672 HCl): A Multitransmitter Approach to Dementia Treatment*, CNS Drug Reviews, Vol. 8 No. 2	(2002)	143-158
59	Huff, *et al.*, *Potential Clinical Use of an Adrenergic/Cholinergic Agent (HP128) in the Treatment of Alzheimer's Disease*, Ann NY Acad Sci., 640	(1991)	263-267
60	Ishihara, *et al.*, *Central Selective Acetylcholinesterase Inhibitor with Neurotropic Activity: Structure-Activity Relationships of TAK-147 and Related Compounds Current Medicinal Chemistry*, Curr. Med Chem., Vol. 7	(2000)	341-354
61	Johns C, *et al.*, *The Cholinergic Treatment Strategy in Aging and Senile Dementia* Psychopharmacology Bulletin, Vol. 19 No. 2	(1983)	185-197
62	Johns, C. *et al. Development of Cholinergic Drugs for the Treatment of Alzheimer's Disease*, Drug Development Research, Vol. 5	(1985)	77-96
63	Jhee, *et al.*, *First Clinical Evaluation of Ganstigmine in Patients with Probable Alzheimer's Disease*, Clin. Neuropharmacology, 29(3)	(2003)	164-169
64	Kewitz, *et al*, *Galanthamine in Alzheimer's Disease* Alzheimer's Disease: Therapeutic Strategies	(1994)	140-144
65	Krauz V, *et al.*, *Role of Cholinergic Mechanisms in ATFase Activity and Glycolysis Intensity Regulation in the Rat Neocortex, Hippocampus and Truncus Cerebri*, Farmakologia I Toksikologia, Vol. 1	(1982)	23-26
66	Levy M, *et al.*, *Research Subject Recruitment for Gerontological Studies of Pharmacological Agents*, Neurobiology of Aging, 3(1)	(1982)	77-79
67	Liston, *et al.*, *Pharmacology of Selective Acetylcholine Inhibitors: Implications for Use in Alzheimer's Disease*, Eur J Pharmacol., 486(1)	(2004)	9-17

No.	Title	Date	Page Nos.
68	Luria A, *et al,. Restoration of Higher Cortical Function Following Local Brain Damage*, Disorders of Higher Nervous Activity, Chapter 21	(1969)	368-433
69	Maelicke, A., *et al., Allosterically Potentiating Ligands of Nicotinic Receptors as a Treatment Strategy for Alzheimer's Disease,* Behav. Brain Res., Vol.113	(2000)	119-206
70	Marin, D. *et al. Impact of Rivastigmine on Costs and Time Spent in Caregiving for Families of Patients with Alzheimer's Disease*, International Pyschogeriatrics, 15	(2003)	385-398
71	Marriott, *et al., Blood Choline Levels and Delayed Response Performance in Young and Old Monkeys*, Soc. Neurosci. Abst., 7	(1981)	950
72	Matsey, V. *et al. Donepezil Reduces The Time Caregivers Spend Providing Care: Results of a one-year, double blind, randomized trial in patients with mild to moderate Alzheimer's disease*, American Journal of Geriatric Psychiatry	(2001)	78-79
73	Mohs R, *et. al., Studies of Cholinergic Drug Effects on Cognition in Normal Subjects and Patients with Alzheimer's Disease* Aging, Vol. 17	(1981)	225-230
74	Mohs R, *et al., Clinical Studies of the Cholinergic Deficit in Alzheimer's Disease*, J. of the Am. Geriatrics Soc'y, 33(11)	(1985)	749-757
75	Mohs R, *et al., Oral Physostigmine Treatment of Patients With Alzheimer's Disease*, Am. J. of Psychiatry, 142(1)	(1985)	28-33
76	Mohs R, *et. al., Interaction of Choline and Scopolamine in Human Memory*, Life Sciences, Vol. 37	(1985)	193-197
77	Mohs R, *et al., Choline Chloride Effects on Memory: Correlation*	(1980)	149-156

No.	Title	Date	Page Nos.
	with the Effects of Physostigmine, Psychiatry Res., Volume 2, Issue 2		
78	Mohs, *et al. Intravenous and Oral Physostigmine in Alzheimer's Disease*, Interdisciplinary Topics in Gerontology, Vol. 20	(1985)	140-152
79	Paskov, D.S. *Galanthamine*, New Neuromuscular Blocking Agents, Handbook of Experimental Pharmacology, Vol. 79	(1986)	653-672
80	Pernov K, *et al., Nivalin and its Curative Effect Upon Diseases of the Nervous System*, Psychiatry and Neurology and Medical Psychology Bulletin on Research and Practice, 13(11)	(1961)	4316-4320
81	Pereira, E.F. *et al. Identification and Functional Characterization of a new Agonist Site on Nicotinic Acetylcholine Receptors of Cultured Hippocampal Neurons*, J. Pharmacol. Exp. Ther., 265(3)	(1993)	1474-1491
82	Peters B, *et al , Effects of Physostigmine and Lecithin on Memory in Alzheimer Disease*, Annals of Neurology, 6(3)	(1979)	219-221
83	Plaitakis A, *et al., Homer's Moly Identified As Galanthus Nivalis L.: Physiologic Antidote to Stramonium Poisoning*, Clinical Neuropharmacology, 6(1)	(1983)	1-5
84	Pomora, N., *et al., A Dose-Ranging Response Study of Lecithin in the Treatment of Alzheimer's Disease, in* Alzheimer's Disease: A Report on Progress, Vol. 19	(1982)	379-383
85	Pomora, N., *et al., Failure of Single-Dose Lecithin to Alter Aspects of Central Cholinergic Activity in Alzheimer's Disease*, J Clin. Psychiat., 44	(1983)	293-295
86	Pomora, N., et al., *Combined Cholinergic Precursor Treatment and Dihydroergotoxine Mesylate*, Alzheimer's Disease, IRCS Med Sci., 11	(1983)	1048-1049
87	Rainer, R., *Clinical Studies With Galanthamine*, Drugs of Today, Vol.	(1997)	273-278

No.	Title	Date	Page Nos.
	33 No. 4		
88	Rathmann K, et al., *Alzheimer's Disease: Clinical Features, Pathogenesis, and Treatment*, Drug. Intell. Clin. Pharm., 18	(1984)	684-691
89	Studzinski, *et al., The Canine Model of Human Cognitive Aging and Dementia: Pharmacological Validity of the Model for Assessment of Human Cognitive-Enhancing Drugs,* Prog. Neuro-Psychopharm. Biol. Psychiat., 29	(2005)	468-498
90	Smith C, *et al , Possible Biochemical Basis of Memory Disorder in Alzheimer Disease* Annals of Neurology, Vol. 5 No. 6	(1978)	471-473
91	Smith C, *et al , Physostigmine in Alzheimer's Disease*, The Lancet, 1	(1979)	42
92	Snape, *et al., A Comparative Study in Rats of the In Vitro and In Vivo Pharmacology of the Acetylcholinesterase Inhibitors Tacrine, Donepezil and NXX-066,* Neuropharmacol., 38	(1999)	181-193
93	Sramek, *et al., NXX-066 in Patients with Alzheimer's Disease: A Bridging Study,* Life Sci, 64(14)	(1999)	1215-1221
94	Summers, *et al., Use of THA in Treatment of Alzheimer-Like Dementia: Pilot Study in 12 Patients*, Biological Psychiatry, Vol. 16	(1981)	145-153
95	Summers, W., *Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia*, New England Journal of Medicine	(1986)	1241-1245
96	Sweeny J., *et al , The Effects of Different Doses of Galanthamine, A Long-Lasting Acetylcholinesterase Inhibitor on Memory in Mice*, Psychopharmacology, Vol. 102	(1990)	191-200
97	Sweeny J., *et al., Galanthamine, an Acetylcholinesterase Inhibitor: A time Course of the Effect on Performance and Neurochemical Parameters in Mice*, Pharmacology, Biochemistry & Behavior, Vol. 34	(1989)	129-137

No.	Title	Date	Page Nos.
98	Sweeny J., *et al*, *A Long-Acting Cholinesterase Inhibitor Reverses Spatial Memory Deficits in Mice* Pharmacology, Biochemistry & Behavior, Vol. 31	(1988)	141-147
99	Thal L, *et al*., *Memory Enhancement With Oral Physostigmine In Alzheimer's Disease*, The New England Journal of Medicine, 308(12)	(1983)	720-721
100	Vroulis, G., *et al*., *Effects of Lesions on Memory and Behavior in Alzheimer's Type Dementia*, Psychopharacol Bulletin, Vol. 17	(1981)	127-128
101	Wang, *et al*., *Progress in Studies of Huperzine A, A Natural Cholinesterase Inhibitor from Chinese Herbal Medicine,* Acta Pharmacologica Sinica, Vol. 27	(2006)	1-26
102	Whitehouse, *et al*., *Alzheimer's Disease: Evidence for Selective Loss of Cholinergic Neurons in the Nucleus Basalis*, Annals of Neurology, Vol. 10	(1981)	122-126
103	Whitehouse, *et al*., *Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain*, Science, Vol. 215	(1982)	1237-1239
104	Wilcock, G., *et al*., *A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer's Disease,* Drugs Aging, 20	(2003)	777-789
105	Wurtman, *Activation of Neurotransmitters in the Brain: Strategies in the Treatment of AD/SDAT*, Normal Aging, Alzheimer's Disease and Senile Dementia: Aspects on Etiology, Pathogenesis, Diagnosis and Treatment	(1985)	275-280
106	Wurtman, *et al. Lecithin Consumption Increases Acetylcholine Concentrations in Rat Brain and Adrenal Gland*, Science, Vol. 202	(1978)	223-225

No.	Title	Date	Page Nos.
107	Zemlan, F.P., *et al.*, *Velnacrin for the Treatment of Alzheimer's Disease: A Double-Blind, Placebo-Controlled trial. The Mentane Study Group,* Journal of Neural. Trans., Vol. 103	(1996)	1105-1116
108	*Neurochemische Untersuchungen*, by Dr. Michael Rainer (and English translation thereof)	(1985)	DX 00611 00011-00014
109	Letter from Dr. Werner Frantsits to John Richards re galanthamine	(1995)	DX 00095 - 00001
110	Letter from Dr. Werner Frantsits and Dr. Hermann Mucke to Dr. Bonnie Davis re galanthamine patents	(1994)	DX 00007 -00001
111	*Warum Nivalin Zur Therapie Des M. Alzheimer?* by Dr. Michael Rainer (and English translation thereof)	(1985)	DX 00611 -00010

Defendants reserve the right to amend and/or supplement this notice, at least 30 days before trial, if commencement of trial in this matter is changed form its currently scheduled date of May 21, 2007. Additionally, Defendants reserve the right to amend and/or supplement this notice to add additional items to this statement that were previously cited to Plaintiffs and were inadvertently omitted. The above list is exemplary rather than exhaustive and, therefore, should not be understood to limit the evidence or testimony Defendants may present or adduce at trial regarding the subject matter required to be disclosed pursuant to 35 U.S.C. § 282.

Respectfully submitted,

PHILLIPS, GOLDMAN & SPENCE, P.A.

By: 

John C. Phillips, Jr. (#110)
Brian E. Farnan (#4089)
1200 North Broom St.
Wilmington, DE 19806
Tele: (302) 655-4200
Fax: (302) 655-4210
JCP@pgslaw.com

and

George C. Lombardi *(admitted pro hac vice)*
Taras A. Gracey *(admitted pro hac vice)*
Lynn M. Ulrich *(admitted pro hac vice)*
Mustafa A. Hersi *(admitted pro hac vice)*
David T. Bower *(admitted pro hac vice)*
WINSTON & STRAWN LLP
35 West Wacker Drive
Chicago, Illinois 60601
Tele: (312) 558-5600
Fax: (312) 558-5700
lulrich@winston.com

Attorneys for Defendants/Counterclaim-Plaintiffs Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc.

Date: April 20, 2007